Health-related quality-of-life results from the randomised phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact first-recurrence World Health Organization grade 2 and 3 glioma (European Organization for Research and Treatment of Cancer 26091)-Reference-Cited by-同舟云学术

Health-related quality-of-life results from the randomised phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact first-recurrence World Health Organization grade 2 and 3 glioma (European Organization for Research and Treatment of Cancer 26091)

Published:2023-09 Issue: Volume:190 Page:112946
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Reijneveld Jaap C.,Machingura Abigirl^ORCID,Coens Corneel,Taphoorn Martin J.B.,Taal Walter^ORCID,Clement Paul M.,Idbaih Ahmed^ORCID,de Vos Filip Y.F.,Klein Martin^ORCID,Wick Wolfgang,Mulholland Paul J.,Lewis Joanne,Golfinopoulos Vassilis^ORCID,Ghislain Irina,Bottomley Andrew,van den Bent Martin J.

Funder

European Organisation for Research and Treatment of Cancer

Roche

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference28 articles.

1. Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial;Van den Bent;Lancet Oncol,2018

3. Review on quality of life issues in patients with primary brain tumors;Taphoorn;Oncologist,2010

4. Cognitive status and quality of life in patients with suspected versus proven low-grade gliomas;Reijneveld;Neurology,2001

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. General population normative values for the EORTC QLQ-C30 by age, sex, and health condition for the French general population;Journal of Patient-Reported Outcomes;2024-05-02

2. Global health status and fatigue score in isocitrate dehydrogenase-mutant diffuse glioma grades 2 and 3: A longitudinal population-based study from surgery to 12-month follow-up;Neuro-Oncology Practice;2024-03-01

3. Nanomedicine facilitated cell signaling blockade: difficulties and strategies to overcome glioblastoma;Journal of Materials Chemistry B;2024

4. The role of angiogenic growth factors in the immune microenvironment of glioma;Frontiers in Oncology;2023-09-13